Cuál es el precio por Venus Medtech (Hangzhou) Inc. (2500)

Precio por Venus Medtech (Hangzhou) Inc. (2500) es de$0.13048475

Cuál es la capitalización de mercado por Venus Medtech (Hangzhou) Inc. (2500)

Capitalización de mercado por Venus Medtech (Hangzhou) Inc. (2500) es $57.55M

Venus Medtech (Hangzhou) Inc. (2500) Ratio P/S

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.

Año	Ratio P/S	Cambiar
Not enough data for the provided dates.

Año

Ratio P/S

Cambiar

Not enough data for the provided dates.

Empresa	Ratio P/S	Diferencia del ratio P/S	País
STERIS plc STE.US	3.77	-	IE
Shanghai United Imaging Healthcare Co., Ltd. 688271.SS	-	-	CN
Ypsomed Holding AG YPSN.SW	-	-	CH
Medacta Group S.A. MOVE.SW	-	-	CH
Jafron Biomedical Co.,Ltd. 300529.SZ	-	-	CN

Empresa

Ratio P/S

Diferencia del ratio P/S

País